TaiMed Biologics (4147) — Cash Flow-to-Debt Ratio
TaiMed Biologics (4147) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2026, meaning its operating cash flow of NT$-45.01 Million could theoretically repay 0% of its total liabilities (NT$836.32 Million) in one year. See 4147 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
TaiMed Biologics Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for TaiMed Biologics across 11 annual periods. For the full cash flow conversion analysis, see 4147 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for TaiMed Biologics (2015–2025)
Year-by-year debt coverage analysis for TaiMed Biologics. Check TaiMed Biologics earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | NT$191.14 Million | NT$953.05 Million | ▲ +151.6% |
| 2024 | -0.39x | NT$-379.55 Million | NT$976.34 Million | ▼ -1916.3% |
| 2023 | -0.02x | NT$-25.60 Million | NT$1.33 Billion | ▲ +95.6% |
| 2022 | -0.44x | NT$-605.21 Million | NT$1.39 Billion | ▼ -244.9% |
| 2021 | -0.13x | NT$-211.28 Million | NT$1.67 Billion | ▼ -11.6% |
| 2020 | -0.11x | NT$-201.94 Million | NT$1.78 Billion | ▲ +80.2% |
| 2019 | -0.57x | NT$-655.31 Million | NT$1.14 Billion | ▲ +22.2% |
| 2018 | -0.74x | NT$-522.86 Million | NT$710.55 Million | ▲ +70.0% |
| 2017 | -2.45x | NT$-516.48 Million | NT$210.71 Million | ▼ -25.2% |
| 2016 | -1.96x | NT$-172.29 Million | NT$87.99 Million | ▲ +88.3% |
| 2015 | -16.76x | NT$-446.26 Million | NT$26.63 Million | — |